Pfizer Cardura Potential Labeling Changes Should Await More Data - Cmte.
Executive Summary
Any potential changes to Pfizer's antihypertensive therapy Cardura (doxazosin) labeling should await additional data from NIH's ALLHAT study, FDA's Cardiovascular & Renal Drugs Advisory Committee said May 24.
You may also be interested in...
Risk Cmte. Member Furberg Is On Record Pro Long Trials, Con Pfizer Drugs
FDA's new risk management subcommittee has a prominent and widely published member with strong predilections for long clinical trials showing clear clinical benefit, especially for follow-on compounds in an established class
Risk Cmte. Member Furberg Is On Record Pro Long Trials, Con Pfizer Drugs
FDA's new risk management subcommittee has a prominent and widely published member with strong predilections for long clinical trials showing clear clinical benefit, especially for follow-on compounds in an established class
Baxter Extraneal Phase IV Mortality Study Recommended By FDA Committee
Baxter's dialysis agent Extraneal should be studied in Phase IV trials measuring hypertension and mortality, FDA's Cardiovascular & Renal Drugs Advisory Committee recommended Aug. 9.